Hepalink Group

Hepalink Group is a multinational biopharmaceutical company that was established in 1998 in Shenzhen, China. The company is dual-listed in Hong Kong and mainland China. Its core business is centered around the heparin industrial chain, large molecule biologics CDMO services, and the research, development, and commercialization of innovative drugs. The company's slogan reflects its commitment to discovering, developing, and commercializing high-quality, safe, and effective medicines and services to address patients’ unmet medical needs. Hepalink operates in three synergistic business segments, all of which are dedicated to addressing patients’ unmet medical needs and bringing safe and effective therapies and services to patients around the world. Despite lacking specific information regarding the last investment and the last investment investors, the company's track record and focus on the pharmaceutical industry in China indicate strong growth potential and a commitment to addressing critical healthcare challenges. Overall, Hepalink Group's positioning in the pharmaceutical industry and its dedication to addressing unmet medical needs could make it an attractive investment opportunity for venture capitalists seeking exposure to the rapidly evolving healthcare landscape in China and beyond.